Molecular Pathology Laboratory Network

BRAF

EGFR inhibitor response

Colorectal cancer (CRC), Hereditary non-polyposis colon cancer (HNPCC)

Primer-extension PCR utilizing shifted termination assay (STA) technology followed by capillary electrophoresis (CE)

83890 x2 - Isolation or extraction of highly purified nucleic acid
83892 - Enzymatic digestion
83898 - Amplification, target, each nucleic acid sequence
83900 - Amplification first 2 sequence
83901 x3 - Amplification each additional sequence
83907 - Lysis of cells prior to nucleic acid extraction
83909 - Separation by capillary elecrophresis
83914 - Mutation identification by enzymatic ligation or primer extension, single segment
83912 - Molecular diagnostics, interpretation and report
88305-T – Surgical pathology examination
88305 and 83891 do not apply when BRAF ordered as a reflex from KRAS.

7-10 business days

10% neutral buffered formalin fixed paraffin embedded tissue. (Notify MPLN when other fixatives are used.)
NOTE: Include a surgical pathology report with the sample.

Stable at 18-25°C indefinitely

Ship ambient

Improper specimen labeling; Insufficient sample; Inadequate fixation and/or processing

Positive or Negative for BRAF V600 mutation

KRAS, microsatellite instability

Utilized as an independent predictor of colorectal cancer (CRC) patient responsiveness to EGFR inhibitor therapy and to assist with the differentiation of microsatellite instability high (MSI-H) hereditary non-polyposis colon cancer (HNPCC) from sporadic MSI-H CRC.